



OPEN

# A tailored polylactic acid/ polycaprolactone biodegradable and bioactive 3D porous scaffold containing gelatin nanofibers and Taurine for bone regeneration

Hadi Samadian<sup>1</sup>, Saeed Farzamfar<sup>2</sup>, Ahmad Vaez<sup>3</sup>, Arian Ehterami<sup>4</sup>, Arindam Bit<sup>5</sup>,  
Mostafa Alam<sup>6</sup>, Arash Goodarzi<sup>7</sup>, Gholamhossein Darya<sup>8</sup> & Majid Salehi<sup>9,10</sup>✉

The focus of the current study was to develop a functional and bioactive scaffold through the combination of 3D polylactic acid (PLA)/polycaprolactone (PCL) with gelatin nanofibers (GNFs) and Taurine (Tau) for bone defect regeneration. GNFs were fabricated via electrospinning dispersed in PLA/PCL polymer solution, Tau with different concentrations was added, and the polymer solution converted into a 3D and porous scaffold via the thermally-induced phase separation technique. The characterization results showed that the scaffolds have interconnected pores with the porosity of up to 90%. Moreover, Tau increased the wettability and weight loss rate, while compromised the compressive strengths. The scaffolds were hemo- and cytocompatible and supported cell viability and proliferation. The *in vivo* studies showed that the defects treated with scaffolds filled with new bone. The computed tomography (CT) imaging and histopathological observation revealed that the PLA/PCL/Gel/Tau 10% provided the highest new bone formation, angiogenesis, and woven bone among the treatment groups. Our finding illustrated that the fabricated scaffold was able to regenerate bone within the defect and can be considered as the effective scaffold for bone tissue engineering application.

Bone is a typical complex tissue with a hierarchical structure that supports the body, protects internal organs, facilitates movement, stores, and releases minerals. Bone defects are a serious illness that resulted in post-trauma, osteoporosis, congenital defects, arthritis, and neoplasm, etc. Due to their osteoinductivity and osteoconductivity, bone graft materials, as autografts, allografts, and xenografts have been used for bone defects and fractures treatment. Although they have some advantages, they suffer from the risk of disease transfer, an increase of operative time and cost, possible immunogenicity, and chronic pain<sup>1-4</sup>.

Remarkable attention has been laid toward bone tissue engineering, synthetic and natural biomaterials by orthopedics and researchers to overcome the drawbacks of the existing treatment regimes. Bone tissue engineering as an alternative to the current treatment approaches is the combination of biomaterials as tissue scaffolds

<sup>1</sup>Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. <sup>2</sup>Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medical Sciences and Technologies, Tehran University of Medical Sciences, Tehran, Iran. <sup>3</sup>Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. <sup>4</sup>Department of Mechanical Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran. <sup>5</sup>National Institute of Technology, Raipur, India. <sup>6</sup>Department of Oral and Maxillofacial Surgery, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran. <sup>7</sup>Department of Tissue Engineering, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran. <sup>8</sup>Department of Comparative Biomedical Science, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. <sup>9</sup>Department of Tissue Engineering, School of Medicine, Shahrood University of Medical Sciences, Shahrood, Iran. <sup>10</sup>Tissue Engineering and Stem Cells Research Center, Shahrood University of Medical Sciences, Shahrood, Iran. ✉email: msalehi.te1392@gmail.com

and drug delivery vehicles, cell-stimulating agents, and bone lying cells<sup>5,6</sup>. The most important part of the bone tissue engineering is the scaffold which requires precise designing and processing to mimic the biological, structural, and mechanical properties of natural bone tissue. Inspired by the nature of bone, a proper bone formation and ingrowth requires a 3D, porous, structurally hierarchical nanocomposites and constructs that possess several levels of the organization, i.e., from the molecular arrangement of proteins up to the macroscopic tissue arrangement<sup>7</sup>.

Electrospun nanofibers have gained a great deal of attention as the bone tissue engineering scaffolds due to their promising properties, such as a resemblance to the extracellular matrix (ECM), high surface to volume ratio, flexibility in the fabrication process, and low-cost production<sup>8,9</sup>. A wide range of polymers and biopolymers have been electrospun and applied as the bone tissue engineering scaffolds<sup>10</sup>. Gelatin is a promising biopolymer derived from collagen and has been widely utilized for bone tissue engineering<sup>11,12</sup>. Lee et al. and Zha et al. showed that the incorporation of gelatin into the scaffolds promotes osteoblast cell attachment and proliferation<sup>13,14</sup>. Despite their wide applications in the bone tissue engineering, their translation to the clinics has not been achieved due to their 2D structure. Accordingly, electrospun nanofibers can be incorporated into the 3D structures as the nanocomposite filler<sup>15</sup>.

The thermally-induced phase separation (TIPS) technique is a valuable method to fabricate 3D scaffolds with adjustable porosity and interconnected pores, critical for bone tissue engineering. In this approach, the intended homogenous polymer solution undergoes a phase separation under the proper temperature and separates into polymer-rich and polymer-lean regions. In the final step and after the solvent extraction step, the 3D porous scaffold is obtained<sup>16</sup>. In addition to the structural support, the bioactive molecules are also required for an effective and facilitated bone healing process. Various types of bioactive substances have been evaluated for bone tissue engineering, such as peptides, mineral crystals, and amino acids. Taurine (Tau) is an essential amino acid which its positive effects on bone metabolism and formation have been reported<sup>17–19</sup>. It is a sulfurated  $\beta$ -amino acid that is found in free form in animal sources<sup>20,21</sup>. It is documented that Tau is involved in calcium modulation, osmoregulation, antioxidation, membrane stabilization, neuromodulation, protein phosphorylation regulation<sup>19,22,23</sup>. Accordingly, in the current study, we aimed to combine the positive biological activities of electrospun (GNFs) and Tau with the structural features of the TIP-based scaffold to develop an innovative tissue engineering approach for bone regeneration.

## Results and discussions

**The surface morphology.** SEM was used to evaluate the surface morphology of the cross-sectioned scaffolds, and the results are shown in Fig. 1. The image analysis showed that the fabricated GNFs have average diameter around 194 nm. The results of hydrogel imaging showed that the scaffolds have interconnected pore microstructure, which is critical for cell infiltration, nutrient, and waste transfer.

The pore size measurement using the ImageJ software (version 1.43, <https://imagej.nih.gov/ij/>, National Institutes of Health, Bethesda, Maryland) showed that the incorporating 0.1% Tau increased the pore size of PCL/PLA/GNF hydrogel from  $37 \pm 12$  to  $64 \pm 11$   $\mu\text{m}$ . On the other hand, further elevating the concentration of Tau from 0.1 to 10% did not significantly influence the pore size ( $p < 0.3$ ) and the connection between the pores.


**Wettability measurement.** The wettability is a critical property for scaffolds that determines the interactions of cells and biological fluid proteins with the scaffold<sup>24,25</sup>. Moreover, it impacts the degradation rate of a scaffold in the body<sup>26,27</sup>. The wettability of the prepared scaffold was evaluated with the water contact angle measurement method, and the results are presented in Fig. 2.

The results showed that there is an indirect correlation between the concentration of the Tau and the wettability of the scaffolds. Increasing the concentration of Tau to the scaffolds decreased the water contact angle value due to its hydrophilic nature. The influence of the Tau on the hydrophobicity of the scaffolds was statistically significant in 10% Tau group, which decreased the WCA from  $108.9 \pm 3.4$  for PCL/PLA/GNF to  $81.0 \pm 3.1$  for PCL/PLA/GNF/10% Tau scaffolds. Our previous study also showed that the addition of Tau makes the fabricated dressing more hydrophilic<sup>28</sup>.


**Weight loss.** The implanted scaffolds should be degradable in the body and replaced with the growing bone tissues. Moreover, the rate of the degradation should be in balance with the bone tissue growth, fast degradation left an empty cavity in place, and slow degradation hinders tissue growth. The weight loss of the prepared scaffolds was evaluated as the biodegradation and the results are presented in Fig. 3.

As shown in Fig. 3, the concentration of Tau had a direct effect on the weight loss of the scaffolds and increasing the concentration of Tau increased the weight loss present of the scaffolds on both 30 and 60 days. The scaffold containing 10% Tau showed the highest weight loss of  $\approx 67\%$  on the 60th day. The difference between the scaffolds containing 10% Tau and the other groups was statistically significant ( $p < 0.01$ ) in both 30th and 60th days. The correlation between hydrophobicity and biodegradability can be attributed to the weight loss obtained results<sup>29</sup>. Since the hydrolysis is the main degradation mechanism of the prepared scaffolds, the incorporation of Tau enhanced weight loss through easier accessibility of water molecules to the polymer changes. Diffusion of the degrading medium into the interior of the scaffolds is the first and determinant step of hydrolysis degradation and increasing the hydrophilicity accelerates the flow of medium into the internal structure of scaffolds<sup>30</sup>.

Park et al.<sup>29</sup> reported that there is a direct correlation between the hydrophilicity and biodegradability of poly-esteramides scaffold. They also suggested that this correlation is through easier accessibility of water molecules to polymer chains. In another study, Oh et al.<sup>31</sup> fabricated 3D scaffold from PLGA and PLGA/polyvinyl alcohol (PVA) through the melt-molding particulate leaching method. They reported that the hydrophilization of PLGA scaffold by the addition of PVA accelerate the degradation of the scaffolds. Wu et al.<sup>30</sup> fabricated zein/PCL porous




**Figure 1.** SEM micrograph of the prepared scaffolds. (a) PCL/PLA/GNF, (b) PCL/PLA/GNF/Tau 0.1%, (c) PCL/PLA/GNF/Tau 1%, and (d) PCL/PLA/GNF/Tau 10%. The insets show SEM micrograph of GNFs.



**Figure 2.** The water contact angle value of the prepared scaffolds. \*Significance against PCL/PLA/GNF and PCL/PLA/GNF Tau 0.1% ( $p < 0.05$ ).





**Figure 3.** Histogram comparing the prepared scaffolds weight-loss percentages at the end of 60th day post-incubation. Values represent the mean  $\pm$  SD,  $n = 3$ , \* $p < 0.05$  and \*\* $p < 0.01$  (obtained by Student's *t* test).


scaffolds by solvent casting–particulate leaching method. They reported that the degradation rate of the PCL scaffold was slower than zein/PCL biocomposite and the rate could be adjusted by varying the amount of zein.

**Mechanical property.** A proper bone tissue engineering scaffolds should have acceptable mechanical properties to withstand against the applied stress. The mechanical property of the prepared scaffolds was evaluated using a compression test method, and the obtained compressive strengths were presented in Fig. 4.


As shown in Fig. 4a, the highest compressive strength,  $5.4 \pm 0.4$  MPa, was resulted from PCL/PLA/GNF group and increasing Tau concentration to 10% reduced the compressive strength to  $3.3 \pm 0.22$  MPa. The inverse correlation between the concentration of Tau and the compressive strength can be attributed to the porosity induced by the Tau. The hydrophilic nature of Tau results in more penetration of water molecules and induction of pores with the bigger size and subsequently compromises the mechanical properties<sup>32,33</sup>. Guarino et al.<sup>33</sup> fabricated 3D scaffolds from poly  $\epsilon$ -caprolactone via the phase inversion/salt leaching technique. They reported that there was an inverse correlation between the pore volume fraction and the mechanical strength of the fabricated scaffold.

The functionality of the 3D scaffolds during the tissue engineering applications is substantially related to their porosity and pores size. The porosity of the prepared scaffolds was measured using the liquid displacement method, and the results are presented in Fig. 4b. The results indicated that the porosity value for every scaffold is in the acceptable range and more than 90%. In addition, the incorporation and increasing the concentration of Tau slightly increased porosity percent, while the differences were not statistically significant ( $p < 0.2$ ). Open porous and interconnected networks are critical for nutrition and waste exchange, cell proliferation and migration for neovascularization and tissue formation. Moreover, the porous scaffolds more effectively mimic the native structure of bone tissue and also induce the formation and release of bioactive molecules such as growth factors, cytokines, and hormones<sup>34–36</sup>.

**Blood compatibility test.** Hemocompatibility is the other critical property for an implantable structure—that determinant the interaction of the implanted scaffold with blood cells. The result showed that the hemolysis percent of the prepared scaffolds were lower than the positive control, and the differences are statistically significant ( $p < 0.05$ ). The results indicated that the prepared scaffolds were hemocompatible and the induced hemolysis values were in the acceptable range (Fig. 5).



**Figure 4.** (a) The compressive strength obtained from the compression test method, (b) the porosity values of the prepared scaffolds obtained with the liquid displacement method. Values represent the mean  $\pm$  SD,  $n = 3$ , \* $p < 0.05$  (obtained by Student's t test).




**Figure 5.** Hemolysis percent of the prepared scaffolds. The negative control was zero. Values represent the mean  $\pm$  SD,  $n = 3$ , \* $p < 0.05$  (obtained by Student's t test).

**Cytocompatibility and cell proliferation.** The proliferative effects of the prepared scaffolds were evaluated by the MTT assay method, and the obtained results are presented in Fig. 6. MG-63 cells were cultured on the prepared scaffolds, and the proliferation was measured at 24 h and 72 h after cells seeding.

The results showed that the proliferation of the cells on the Tau containing scaffolds was higher than the control (tissue culture plate) and PCL/PLA/GNF scaffold, 24 h after cell seeding. The highest proliferation was achieved with PCL/PLA/GNF/Tau 10%, and the differences were statistically significant ( $p < 0.01$ ). It is interesting to note that the proliferation of the PCL/PLA/GNF group was lower than the control in both incubation time, and the incorporation of Tau improved the proliferation of the cells. These results indicate that PCL/PLA/GNF/Tau 10% scaffold is suitable for cell growth and proliferation. Our previous study also confirmed that the incorporation of Tau improves the proliferation of cells on the scaffolds<sup>28</sup>.

**In vivo bone formation findings.** X-ray Computed Tomography (CT) as the gold standard imaging method on bone was conducted to assess the bone formation within the created fracture under treatment with



**Figure 6.** The viability and proliferation of MG-63 on the prepared scaffolds. Values represent the mean  $\pm$  SD,  $n = 3$ , \* $p < 0.05$ , \*\* $p < 0.01$  (obtained by Student's t test).

the fabricated scaffolds. The images were obtained 12 weeks post-implantation of the scaffolds, and the results are presented in Fig. 7.


As shown in Fig. 7, there are not any signs of new bone formation within the fracture in the negative control group. These images imply that the animal body was not able to heal the damaged bone during 12 weeks. On the other hand, it is apparent that the application of the fabricated scaffolds induced new bone formation. The highest bone formation was obtained with PCL/PLA/GNF/Tau 10%. The histopathological evaluations were conducted using the H&E and MTC staining to further assess the bone healing process in each group (Figs. 8, 9).

As shown in Figs. 8 and 9, the bone defects treated with PCL/PLA/GNF/Tau 1% and PCL/PLA/GNF/Tau 10% scaffold resulted in higher new bone formation compared with the other groups. Moreover, it was observed that in the negative control and PCL/PLA/GNF groups, the defects filled with a loose areolar connective tissue (LACT) (star) that consisted of haphazardly oriented immature collagen fibers, fibroblasts, and newly-formed blood vessels. The results showed that the implanted scaffolds were degraded and almost replaced with the new tissues, including mature bone (MB), and neo-bone (NB). The highest NB, angiogenesis, and woven bone were obtained with treatment by PCL/PLA/GNF/Tau 1% and PCL/PLA/GNF/Tau 10%. While the negative control resulted in the highest LACT, indicating that the defect was not able to heal during 2 months completely by itself.

The positive effect of Tau on bone metabolism and regeneration are reported in other studies. Mi-Ja Choi<sup>37</sup> showed the beneficial effect of Tau supplementation on femur bone mineral content. In another study, Park et al.<sup>38</sup> reported collagen synthesis, tyrosine phosphorylation, and alkaline phosphatase activity stimulation in UMR-106 cells under treatment with Tau. They suggested that the observed effect was conducted through the ERK2 signaling pathway. Moreover, Moon et al.<sup>23</sup> observed that Tau over-expressed Insulin-like growth factor 1 (IGF-1) and serum level of IGF-1 through the phosphorylations of JAK2 and STAT5. They observed that these molecular changes enhance growth plate length, bone volume density (BV/TV), trabecular thickness (Tb.Th), and total porosity. Our findings were in agreement with these conducted studies with the difference in the application route.

## Conclusion

Tissue engineering is an innovative approach toward the regeneration of damaged tissues using the combination of tailored structures as the scaffolds with bioactive substances. The focus of the present study was to develop a functional and bioactive 3D scaffold-based on PCL/PLA containing GNFs and Tau fabricated via the TIPS method. Our results demonstrated that the fabricated scaffolds exhibited bone-regenerating-favorable features such as suitable pore size and interconnected porosity, acceptable hydrophilicity, weight loss, mechanical properties, and hemo- and cytocompatibility. However, the effects of Tau oral administration on bone metabolism



**Figure 7.** X-ray Computed Tomography (CT) images of damage skull bone. The images were obtained 12 weeks post-implantation.

and parameters have been evaluated in previous studies, and our study is the first report on the application of a TIPS-based scaffold containing Tau on bone regeneration. Our results revealed that the fabricated PCL/PLA/Gel/Tau 3D scaffold supports bone cell proliferation *in vitro* and bone regeneration *in vivo*.


## Materials and methods

**Materials and reagents.** Poly (L-lactic acid) (PLA, Mw = 60 kDa), Gelatin powder (bovine skin, type B), poly ( $\epsilon$ -caprolactone) [PCL; Mw = 48–90 kDa], Tau  $\geq 99\%$ , glutaraldehyde (GA) 25% in H<sub>2</sub>O, ketamine, xylazine, and MTT assay kit were purchased from Sigma-Aldrich (St. Louis, MO). Dimethyl sulfoxide (DMSO), 1,4-dioxane, and acetic acid (AA) were purchased from Merck (Darmstadt, Germany). Dulbecco's modified Eagle's medium DMEM, fetal bovine serum (FBS), penicillin and streptomycin were purchased from GIBCO (Grand Island, NY, USA). MG-63 cells and adult male Wistar rats (3 months old, weighing 250–270 g) were obtained from Pasteur Institute, Tehran, Iran.

**Synthesis of electrospun GNFs.** A commercial electrospinning device (Fanavaran-nano-meghyas Ltd co Tehran Iran) was used to fabricate GNFs based on our previous study<sup>39</sup>. Briefly, based on our previous study<sup>40</sup>, a 40% (w/v) concentration gelatin solution was obtained by dissolving gelatin powder in AA aqueous [75% (v/v)] under stirrer at room temperature. The applied voltage of 20 kV, feeding rate of 0.40 ml/h, and nozzle to collector distance of 15 cm were chosen as the electrospinning parameters. The fabricated nanofibrous mat was cross-linked with GA 1% for 6 h and then washed by DW several times. The residual GA was neutralized using glycine solution. The neutralized GNFs was transferred to a nitrogen tank and after 24 h crushed to small pieces (GNFs).

**Fabrication of PCL/PLA/GNFs scaffold containing Tau using thermally induced phase separation technique.** According to our previous studies<sup>41,42</sup>, PLA and PCL with the mass ratio of 1:1 were dissolved in 1,4-dioxane to form a 10% (w/v) solution. Then GNF (10% w/w) was added to 10 ml of the prepared PCL/PLA solution with 40% weight of PCL/PLA. Tau was added to the prepared solution and stirred at room temperature for 12 h to obtain the final concentrations of 0.1%, 1%, and 10% of Tau in PCL/PLA/GNF solution. The mixtures were frozen at  $-80\text{ }^{\circ}\text{C}$  for 24 h and freeze-dried (Telstar, Terrassa, Spain) for 48 h, and the dried scaffolds were obtained after freeze-drying.






**Figure 8.** Histopathological sections from the calvarial bone defects treated with the scaffolds. (Stained with H&E). *LACT* Loose areolar connective tissue (star), *NB* new bone formation (thick arrow), *MB* mature bone (arrowhead).

**Characterization of the scaffolds.** *Surface morphology.* The surface morphology of the prepared scaffolds was observed by using a Scanning Electron Microscope (SEM; Philips XL-30) at the accelerating voltage of 15 kV. The SEM images were obtained from the cross-section of the scaffolds after freeze-drying and sputter coating with a thin layer of gold.

*Contact angle measurement.* The wettability of the prepared scaffolds was evaluated using a water contact angle measuring system (G10, KRUSS, Germany) in the static mode with the sessile drop method. Five samples were used for each test, and the average value was reported with standard deviation ( $\pm$ SD).





**Figure 9.** Histopathological sections from the calvarial bone defects treated with the scaffolds. (Stained with TCM). *LACT* loose areolar connective tissue (star), *NB* new bone formation (thick arrow), *MB* mature bone (arrowhead).

**Weight loss assessment.** The weight loss measurement was carried out according to our previous paper<sup>43</sup>. Briefly, the prepared scaffolds were gently cut into 20 mm diameter disks, weighed, and immersed in the glass test tubes filled with 15 ml of PBS containing 250 ng/ml amphotericin B, 100 unit/ml penicillin, and 100 µg/ml of streptomycin. The samples were maintained at 37 °C in an incubator for 60 days. After the selected time points, the scaffolds were recovered and dried to a constant weight. Equation (1) was used to calculate the weight loss, where “ $W_0$ ” is the initial weight of samples and “ $W_1$ ” is the dry weight after removing from the media:

$$\text{Weight loss (\%)} = \frac{W_0 - W_1}{W_0} \times 100 \quad (1)$$

**Mechanical properties measurement.** The compression test method was applied to evaluate the mechanical properties of the scaffolds<sup>43</sup>. Three dried cylindrical samples of each scaffold (height and diameter of 20 mm and 10 mm, respectively) were prepared and evaluated using a mechanical testing machine (Santam, Karaj, Iran) at a crosshead speed of 0.5 mm/min. The apparatus was equipped to a 1 kN load cell.

**Porosity assessment.** The liquid displacement method was used to determine the porosity of the prepared scaffolds based on Eq. (2)<sup>39</sup>

$$\text{Porosity (\%)} = \frac{V_1 - V_3}{V_2 - V_3} \times 100 \quad (2)$$

where  $V_1$  is the initial volume of absolute ethanol,  $V_2$  is its volume after scaffold soaking (and ethanol filled the pores), and  $V_3$  is the volume of the ethanol after the scaffold removal.

**Blood compatibility evaluation.** The hemocompatibility test was carried out on human fresh anticoagulated blood collected from volunteers. The study was approved by the Ethics Committee in Kermanshah University of Medical Sciences (Ethics board approval number: IR.KUMS.REC.1397.545). The methods in the study were in accordance with the guidelines of the Declaration of Helsinki. Written informed consent was obtained from all subjects before blood donation. The Each scaffold was incubated with 0.2 ml of the blood diluted with normal saline for 60 min at 37 °C. After passing the incubation time, the incubated blood was centrifuged at 1,500 rpm for 10 min and the resulted supernatant transferred to a 96-well plate, and the absorbance was measured at 545 nm by utilizing the Anthos 2020 (Biochrom, Berlin, Germany) microplate reader. The absorbance was attributed to the hemoglobin leaked from red blood cells (RBC) and hemolysis degree was calculated using Eq. (3)<sup>43</sup>:

$$\text{Hemolysis \%} = \frac{D_t - D_{nc}}{D_{pc} - D_{nc}} \times 100 \quad (3)$$

where  $D_t$ ,  $D_{nc}$ , and  $D_{pc}$  are the absorbance of the sample, the absorbance of the negative control, and the absorbance of the positive control. The negative and positive controls were 0.2 ml of blood diluted with normal saline and deionized water, respectively.

**Cell viability and proliferation assessment.** MTT assay was used to quantitatively measure the viability and proliferation of MG-63 cells cultured on the prepared scaffolds. The samples were punched circularly and put at the bottom of the 96-well plate and sterilized with UV light 15 min. MG-63 cells at a density of  $7 \times 10^3$  cells/sample were seeded onto the samples and incubated for 1 and 3 days under standard culturing conditions. At each time point: the culture media was depleted, cells were washed with sterile PBS three times, and 150  $\mu$ l of new DMEM containing 20  $\mu$ l of 5 mg/ml MTT solution was added to each well followed by incubation for 4 h. After passing this incubation time and formation of purple formazan crystals, the media was replaced with 100  $\mu$ l DMSO to dissolve the formazan crystals. Then, 100  $\mu$ l aliquots were transferred to a 96-well plate, with three replicates per sample and the absorption was read at 570 nm using a microplate reader.

**In vivo studies.** The healing efficacy of the prepared scaffolds was examined in an animal model. The animal studies were conducted based on the ethical committee of Kermanshah University of Medical Sciences and were carried out in accordance with the university guidelines. Thirty healthy adult male Wistar rats were randomly divided into five groups (six rats per group). The groups include (1) PCL/PLA/GNF scaffold without Tau, (2) PCL/PLA/GNF/0.1% Tau scaffold, (3) PCL/PLA/GNF/1% Tau scaffold, (4) PCL/PLA/GNF/10% Tau scaffold, and (5) Negative control group. The animals were anesthetized by intraperitoneal injection of Ketamine 100 mg/ Xylazine 10 mg/kg bodyweight. A trephine (Meisinger) with an external diameter of 7 mm and an internal diameter of 6 mm at a speed rate of 1,000 rpm was used to make a 7 mm spherical incision in the calvaria (skull) of the animals. Subsequently, the prepared scaffolds were put into the defects and the periosteum was repositioned and closed with No. 6.0 nylon suture (SUPA medical devices, Tehran, Iran). No. 3.0 nylon suture (SUPA medical devices, Tehran, Iran) was used to close the skin.

**3D-computed tomography (CT) imaging.** Somatom Emotion CT scanning system (Siemens, Erlangen, Germany) was used to visualize bone formation at the end of 12th-week post-operation.

**Histological analysis.** The histological analysis was conducted according to our previous study<sup>41</sup>. Briefly, the animals were euthanized 12th-week post-operation and the harvested tissues were fixed in neutral buffered formalin (NBF, 10%; pH 7.26) for 48 h. The treated bones were decalcified by storage in nitric acid (5% v/v) for 10 days. The decalcified bones then went through histological fixation and dehydration processes, embedded in paraffin. Sections (5  $\mu$ m thick) were cut and stained with Haematoxylin and Eosin (H&E) and Masson's trichrome (MCT). The resulted histological slides were evaluated by the independent pathologist, using light microscopy (Olympus BX51; Olympus, Tokyo, Japan). The amount of the newly formed cartilage or bone was



assessed as well as the amount of the remaining implants in the total area of the section. Furthermore, the histomorphometric analysis was carried out and the appearance and number of different cells including; fibroblasts, fibrocytes, chondroblasts, chondrocytes, osteoblasts, osteocytes, giant cells, macrophages, lymphocytes, neutrophils, as well as other constituents such as blood vessels, and new cartilage and bone tissues were studied. The resulted data were analyzed using Image-Pro Plus (version 6, Media Cybernetics, Inc., <https://www.media.com/imageproplus>, Silver Spring, USA).

**Statistical analysis.** The results were statistically analyzed by Minitab (version 17, Minitab Inc., <https://www.minitab.com/en-us/>, State College, USA) software using Student's t-test and the data were expressed as the mean  $\pm$  standard deviation (SD)<sup>43</sup>. In all evaluations,  $p < 0.05$  was considered as statistically significant.

**Ethical approval.** The study was approved by the Ethics Committee in Kermanshah University of Medical Sciences (Ethics board approval number: IR.KUMS.REC.1397.545). The methods in the study were in accordance with the guidelines of the Declaration of Helsinki. Written informed consent was obtained from all subjects before blood donation. The animal study was conducted on 30 male adult Wistar rats after approval of the ethics committee of Kermanshah University of Medical Sciences (Ethics board approval number: IR.KUMS.REC.1397.545). All applicable international, national and institutional guidelines for the care and use of animals were followed.

### Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Received: 12 May 2020; Accepted: 14 July 2020

Published online: 07 August 2020

### References

- Venkatesan, J., Bhatnagar, I., Manivasagan, P., Kang, K.-H. & Kim, S.-K. Alginate composites for bone tissue engineering: A review. *Int. J. Biol. Macromol.* **72**, 269–281 (2015).
- Moore, W. R., Graves, S. E. & Bain, G. I. Synthetic bone graft substitutes. *ANZ J. Surg.* **71**, 354–361 (2001).
- Finkemeier, C. G. Bone-grafting and bone-graft substitutes. *JBJS* **84**, 454–464 (2002).
- Eslami, M. *et al.* Fiber-reinforced hydrogel scaffolds for heart valve tissue engineering. *J. Biomater. Appl.* **29**, 399–410 (2014).
- Brunet-Maheu, J.-M. *et al.* Pluronic F-127 as a cell carrier for bone tissue engineering. *J. Biomater. Appl.* **24**, 275–287 (2009).
- Aizenberg, J. *et al.* Skeleton of *Euplectella* sp.: Structural hierarchy from the nanoscale to the macroscale. *Science* **309**, 275–278 (2005).
- Sprio, S. *et al.* Biomimesis and biomorphic transformations: New concepts applied to bone regeneration. *J. Biotechnol.* **156**, 347–355 (2011).
- Abbasian, M., Massoumi, B., Mohammad-Rezaei, R., Samadian, H. & Jaymand, M. Scaffolding polymeric biomaterials: Are naturally occurring biological macromolecules more appropriate for tissue engineering? *Int. J. Biol. Macromol.* **134**, 673–694 (2019).
- Samadian, H., Mobasheri, H., Hasanpour, S. & Faridi-Majid, R. Needleless electrospinning system, an efficient platform to fabricate carbon nanofibers. *J. Nano Res.* **50**, 78–89 (2017).
- Ramalingam, M. *et al.* Nanofiber scaffold gradients for interfacial tissue engineering. *J. Biomater. Appl.* **27**, 695–705 (2013).
- Massoumi, B., Ghandomi, F., Abbasian, M., Eskandani, M. & Jaymand, M. Surface functionalization of graphene oxide with poly(2-hydroxyethyl methacrylate)-graft-poly( $\epsilon$ -caprolactone) and its electrospun nanofibers with gelatin. *Appl. Phys. A* **122**, 1000 (2016).
- Massoumi, B. & Jaymand, M. Chemical and electrochemical grafting of polythiophene onto poly(methyl methacrylate), and its electrospun nanofibers with gelatin. *J. Mater. Sci. Mater. Electron.* **27**, 12803–12812 (2016).
- Zha, Z., Teng, W., Markle, V., Dai, Z. & Wu, X. Fabrication of gelatin nanofibrous scaffolds using ethanol/phosphate buffer saline as a benign solvent. *Biopolymers* **97**, 1026–1036 (2012).
- Lee, J. *et al.* The effect of gelatin incorporation into electrospun poly(L-lactide-co- $\epsilon$ -caprolactone) fibers on mechanical properties and cytocompatibility. *Biomaterials* **29**, 1872–1879 (2008).
- Iwasaki, N. Development of cartilage tissue engineering techniques based on biomedical research. *J. Orthop. Sci.* **19**, 699–706 (2014).
- Szostakiewicz, K. *et al.* The influence of hydroxyapatite content on properties of poly(L-lactide)/hydroxyapatite porous scaffolds obtained using thermal induced phase separation technique. *Eur. Polymer J.* **113**, 313–320 (2019).
- Yuan, L.-Q. *et al.* Taurine transporter is expressed in osteoblasts. *Amino Acids* **31**, 157–163 (2006).
- Kim, S.-J., Lee, H. W. & Gupta, R. C. Taurine, bone growth and bone development. *Curr. Nutr. Food Sci.* **4**, 135–144 (2008).
- Zhang, L.-Y. *et al.* Taurine inhibits serum deprivation-induced osteoblast apoptosis via the taurine transporter/ERK signaling pathway. *Braz. J. Med. Biol. Res.* **44**, 618–623 (2011).
- Tsuboyama-Kasaoka, N. *et al.* Taurine (2-aminoethanesulfonic acid) deficiency creates a vicious circle promoting obesity. *Endocrinology* **147**, 3276–3284 (2006).
- Chate, A. V., Shaikh, B. A., Bondle, G. M. & Sangle, S. M. Efficient atom-economic one-pot multicomponent synthesis of benzylpyrazolyl coumarins and novel pyrano [2, 3-c] pyrazoles catalysed by 2-aminoethanesulfonic acid (taurine) as a bio-organic catalyst. *Synth. Commun.* **49**, 2244–2257 (2019).
- Choi, M.-J. & Chang, K. J. *Taurine* Vol. 8, 335–345 (Springer, New York, 2013).
- Moon, P. D. *et al.* Taurine, a major amino acid of oyster, enhances linear bone growth in a mouse model of protein malnutrition. *BioFactors* **41**, 190–197 (2015).
- Kim, M. S. *et al.* Adhesion behavior of human bone marrow stromal cells on differentially wettable polymer surfaces. *Tissue Eng.* **13**, 2095–2103 (2007).
- Ranella, A., Barberoglou, M., Bakogianni, S., Fotakis, C. & Stratakis, E. Tuning cell adhesion by controlling the roughness and wettability of 3D micro/nano silicon structures. *Acta Biomater.* **6**, 2711–2720 (2010).
- Hu, J., Prabhakaran, M. P., Ding, X. & Ramakrishna, S. Emulsion electrospinning of polycaprolactone: influence of surfactant type towards the scaffold properties. *J. Biomater. Sci. Polym. Ed.* **26**, 57–75 (2015).
- Maretschek, S., Greiner, A. & Kissel, T. Electrospun biodegradable nanofiber nonwovens for controlled release of proteins. *J. Control. Release* **127**, 180–187 (2008).



28. Farzamfar, S. *et al.* Taurine-loaded poly ( $\epsilon$ -caprolactone)/gelatin electrospun mat as a potential wound dressing material: In vitro and in vivo evaluation. *J. Bioactive Comp. Polym.* **33**, 282–294 (2018).
29. Park, C., Kim, E. Y., Yoo, Y. T. & Im, S. S. Effect of hydrophilicity on the biodegradability of polyesteramides. *J. Appl. Polym. Sci.* **90**, 2708–2714 (2003).
30. Wu, F., Wei, J., Liu, C., O'Neill, B. & Ngothai, Y. Fabrication and properties of porous scaffold of zein/PCL biocomposite for bone tissue engineering. *Compos. B Eng.* **43**, 2192–2197 (2012).
31. Oh, S. H., Kang, S. G. & Lee, J. H. Degradation behavior of hydrophilized PLGA scaffolds prepared by melt-molding particulate-leaching method: Comparison with control hydrophobic one. *J. Mater. Sci. Mater. Med.* **17**, 131–137 (2006).
32. Wang, X., Sun, P., Han, N. & Xing, F. Experimental study on mechanical properties and porosity of organic microcapsules based self-healing cementitious composite. *Materials* **10**, 20 (2017).
33. Guarino, V., Causa, F. & Ambrosio, L. Porosity and mechanical properties relationship in PCL porous scaffolds. *J. Appl. Biomater. Biomech.* **5**, 149–157 (2007).
34. Loh, Q. L. & Choong, C. Three-dimensional scaffolds for tissue engineering applications: Role of porosity and pore size. *Tissue Eng. Part B Rev.* **19**, 485–502 (2013).
35. Salerno, A., Di Maio, E., Iannace, S. & Netti, P. Tailoring the pore structure of PCL scaffolds for tissue engineering prepared via gas foaming of multi-phase blends. *J. Porous Mater.* **19**, 181–188 (2012).
36. Hollister, S. J. Porous scaffold design for tissue engineering. *Nat. Mater.* **4**, 518 (2005).
37. Choi, M.-J. Effects of taurine supplementation on bone mineral density in ovariectomized rats fed calcium deficient diet. *Nutr. Res. Pract.* **3**, 108–113 (2009).
38. Park, S., Kim, H. & Kim, S.-J. Stimulation of ERK2 by taurine with enhanced alkaline phosphatase activity and collagen synthesis in osteoblast-like UMR-106 cells. *Biochem. Pharmacol.* **62**, 1107–1111 (2001).
39. Samadian, H. *et al.* Sophisticated polycaprolactone/gelatin nanofibrous nerve guided conduit containing platelet-rich plasma and citicoline for peripheral nerve regeneration: In vitro and in vivo study. *Int. J. Biol. Macromol.* **150**, 380–388 (2020).
40. Salehi, M. *et al.* Polyurethane/Gelatin nanofiber neural guidance conduit in combination with resveratrol and schwann cells for sciatic nerve regeneration in the rat model. *Fibers Polym.* **20**, 490–500 (2019).
41. Shahrezaee, M. *et al.* In vitro and in vivo investigation of PLA/PCL scaffold coated with metformin-loaded gelatin nanocarriers in regeneration of critical-sized bone defects. *Nanomed. Nanotechnol. Biol. Med.* **14**, 2061–2073 (2018).
42. Farzamfar, S. *et al.* Tetracycline hydrochloride-containing poly ( $\epsilon$ -caprolactone)/poly lactic acid scaffold for bone tissue engineering application: In vitro and in vivo study. *Int. J. Polym. Mater. Polym. Biomater.* **68**, 472–479 (2019).
43. Ehterami, A. *et al.* A promising wound dressing based on alginate hydrogels containing vitamin D3 cross-linked by calcium carbonate/D-glucono- $\delta$ -lactone. *Biomed. Eng. Lett.* **10**, 309–319 (2020).

## Acknowledgements

The authors gratefully acknowledge the research council of Kermanshah University of Medical Sciences (Grant no. 97544) for financial support.

## Author contributions

H.S. and M.S. conceptualization and writing- reviewing and editing, S.F., A.V., and A.E. conducted the experiments, A.B. and M.A. data analysis, A.G. and G.D. prepared figures. All authors reviewed the manuscript.

## Competing interests

The authors declare no competing interests.

## Additional information

**Correspondence** and requests for materials should be addressed to M.S.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020